Core Insights - The article discusses the rapid growth and development of immunotherapy for cancer treatment, particularly focusing on immune cell therapies such as CAR-T, CAR-NK, TCR-T, and TIL therapies, which have become a significant fourth modality in cancer treatment alongside surgery, radiation, and drug therapy [1][4]. Industry Overview - Immunotherapy involves collecting young, healthy immune cells, expanding them in vitro, enhancing their targeting capabilities, and reinfusing them into patients to combat pathogens, cancer cells, and mutated cells [1][4]. - The global market for tumor immunotherapy products is projected to grow at a compound annual growth rate (CAGR) of 149.1% from 2017 to 2024, reaching a market size of $7.1 billion by 2025 [1][6]. - In China, the market for tumor immunotherapy products is expected to reach 2.1 billion yuan by 2025, driven by the approval of various immune cell therapy products [1][8]. Development Background - China has the highest incidence and mortality rates of cancer globally, with 4.8247 million new cases and 2.5742 million deaths reported in 2022, accounting for 24.1% and 26.5% of global totals, respectively [4]. - The increasing disposable income of Chinese residents has improved their ability to pay for medical care, with healthcare spending projected to reach 2,547 yuan per capita in 2024, growing by 3.6% [4][5]. Current Market Status - As of the end of 2024, there are 1,040 immunotherapy products in clinical trials, with the U.S. and China leading in the number of trials [10]. - CAR-T therapy is the most commercially mature and widely tested method, with 15 drugs approved globally by December 2025, 8 of which are approved in China [12]. Future Trends - The clinical transformation of immunotherapy is expected to accelerate, with market penetration likely to expand, potentially exceeding 10 billion yuan by 2027 [13]. - Advances in gene editing and AI-assisted target selection are anticipated to enhance treatment precision, while universal and multi-target cell products are expected to become mainstream in research [13][14].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 永泰生物製藥有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06978 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | 本月底法定/註冊股 ...

Core Viewpoint - The company, Yongtai Biotech-B, announced the investment of idle raised funds into two structured deposit products with a total investment amount of 120 million yuan, aiming to enhance fund utilization efficiency while ensuring safety and liquidity [1]. Group 1: Investment Details - The company subscribed to two structured deposit products through the Bank of China on December 8, with a total investment of 120 million yuan [1]. - The first product, with an investment of 20 million yuan, is a principal-protected floating return type linked to the EUR/USD exchange rate, with a term of 20 days and an annualized yield ranging from 0.40% to 1.58% [1]. - The second product, with an investment of 100 million yuan, is also a principal-protected floating return type linked to the NZD/USD exchange rate, with a term of 62 days and an annualized yield ranging from 0.60% to 1.90% [1]. Group 2: Strategic Intent - The company stated that this investment is aimed at improving the efficiency of fund utilization while maintaining safety and liquidity in cash management [1]. - The board believes that the terms of the related transactions are fair and reasonable, aligning with the overall interests of the company and its shareholders [1]. Group 3: Company Background - Yongtai Biotech-B is a leading biopharmaceutical company in China, focusing on the research and commercialization of T-cell immunotherapy for nearly 18 years [1].

Core Viewpoint - Yongtai Bio-B (06978) has announced its investment in structured deposit products from Bank of China, indicating a strategic move to enhance its financial portfolio [1] Group 1: Investment Details - The company subscribed to two structured deposit products on December 8, 2025, with investment values of RMB 20 million and RMB 100 million respectively [1]

Group 1 - The core point of the article is that Yongtai Biological-B (06978.HK) announced an investment in structured deposit products with China Bank, totaling RMB 1.2 billion [1] Group 2 - The company subscribed to two structured deposit products, with investments of RMB 20 million and RMB 100 million respectively [1] - The investment is set to be made on December 8, 2025 [1]

Core Viewpoint - Yongtai Bio-B (06978) announced an investment in structured deposit products with China Bank, totaling RMB 1.2 billion [1] Group 1 - The company subscribed to two structured deposit products, with investments of RMB 20 million and RMB 100 million respectively [1]

Core Viewpoint - Yongtai Biological-B (06978.HK) announced an investment in structured deposit products with China Bank, totaling RMB 1.2 billion [1] Group 1 - The company subscribed to two structured deposit products, with investments of RMB 20 million and RMB 100 million respectively [1]

Immunotech Biopharm Ltd 永泰生物製藥有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 須予披露交易 認購結構性存款產品 認購結構性存款產品 本公司於2025年12月8日向中國銀行股份有限公司認購結構性存款產品I及 結構性存款產品II，投 資 價 值 分 別 為 人 民 幣20,000,000元及人民幣100,000,000 元。 上市規則的涵義 由 於 所 有 結 構 性 存 款 產 品 均 向 中 國 銀 行 股 份 有 限 公 司 認 購 且 性 質 相 似，因 此，就 根 據 上 市 規 則 第14.22條 計 算 相 關 百 分 比 率 而 言，將 於12個月內完成的 每 項 認 購 的 相 應 本 金 已 予 合 計，猶 如 僅 與 中 國 銀 行 股 份 有 限 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06978 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | 本月底法定/註冊股本總額： USD 5,000,000 致：香港交易及結算所有限公司 公司 ...

Core Insights - The latest shareholder equity disclosures for SPROCOMM INTEL (01401), Yongtai Bio-B (06978), and Fortune Industry Trust (87001) were made on November 14, 2025 [1] Group 1: SPROCOMM INTEL (01401) - Shareholder 熊彬 increased holdings from 140 million shares to 210 million shares, representing a holding percentage of 14.00% [2] - Shareholder 李承军 increased holdings from 205 million shares to 307 million shares, representing a holding percentage of 20.50% [2] - Shareholder 鄢雪 increased holdings from 140 million shares to 210 million shares, representing a holding percentage of 14.00% [2] - Shareholder 隋荣梅 increased holdings from 205 million shares to 307 million shares, representing a holding percentage of 20.50% [2] - Shareholder Beyond Innovation Limited increased holdings from 140 million shares to 210 million shares, representing a holding percentage of 14.00% [2] - Shareholder Leap Elite Limited increased holdings from 205 million shares to 307 million shares, representing a holding percentage of 20.50% [2] Group 2: Yongtai Bio-B (06978) - Shareholder 霍志达 reduced holdings from 123 million shares to 0 shares, resulting in a holding percentage of 0% [2] - Shareholder Maxa Financial Group Limited reduced holdings from 123 million shares to 0 shares, resulting in a holding percentage of 0% [2] - Shareholder Maxa Asset Management Limited reduced holdings from 123 million shares to 0 shares, resulting in a holding percentage of 0% [2] - Shareholder 张兆佳 reduced holdings from 123 million shares to 0 shares, resulting in a holding percentage of 0% [2] Group 3: Fortune Industry Trust (87001) - Shareholder Fortune Enrichment Holdings Limited increased holdings from 391 million shares to 392 million shares, representing a holding percentage of 6.01% [2]